Which long‑acting basal insulin is best for nighttime dosing without a sliding‑scale regimen?

Best Insulin for Nighttime Dosing Without Sliding Scale

For nighttime basal insulin without a sliding scale, use bedtime NPH insulin starting at 10 units daily, as recommended by the 2025 American Diabetes Association Standards of Care. 1

Primary Recommendation: NPH Insulin at Bedtime

The ADA specifically endorses bedtime NPH insulin as the initial basal insulin for patients requiring overnight glucose control. 1 This recommendation is particularly strong for scenarios involving predictable nocturnal hyperglycemia patterns, such as overnight tube feeding. 1

Starting Dose and Titration

• Begin with 10 units at bedtime (or 0.1–0.2 units/kg/day if using weight-based dosing). 1
• Titrate by 2 units every 3 days until fasting plasma glucose reaches 80–130 mg/dL without hypoglycemia. 1
• If hypoglycemia occurs without identifiable cause, reduce the dose by 10–20%. 1
• Monitor fasting glucose before breakfast to assess overnight control from the bedtime dose. 1

Alternative: Long-Acting Basal Analogs

Long-acting basal analogs (insulin glargine or detemir) are acceptable alternatives when NPH causes nocturnal hypoglycemia or when evening administration is impractical. 1

Advantages of Long-Acting Analogs Over NPH

Insulin glargine demonstrates superior morning glucose control compared to NPH when both are given at bedtime, with nearly 80% of its glucose-lowering effect in the morning due to reduction of endogenous glucose production. 2 Glargine also produces one-third lower morning glucagon levels compared to NPH. 2

Long-acting analogs reduce nocturnal hypoglycemia risk significantly:

• Meta-analysis shows long-acting insulins reduce nocturnal hypoglycemia with an odds ratio of 0.70 (95% CI 0.63–0.79) compared to intermediate-acting insulins. 3
• Insulin degludec specifically reduces nocturnal hypoglycemia with a rate ratio of 0.697 (95% CI 0.617–0.786) compared to glargine and detemir. 4

Dosing Flexibility Considerations

Insulin degludec offers unique flexibility with its ultra-long duration of action, tolerating day-to-day variation in dose timing while maintaining efficacy and low nocturnal hypoglycemia risk. 5 This may benefit patients with unpredictable schedules or those who find rigid timing burdensome. 5

Practical Implementation

Starting Long-Acting Analogs

• Use the same 10-unit daily starting dose as NPH when initiating glargine or detemir. 1
• Long-acting analogs provide more stable 24-hour coverage with lower nocturnal hypoglycemia risk but at higher cost than NPH. 1

Safety Measures

• Prescribe glucagon for emergency treatment of severe hypoglycemia. 1
• Rotate injection sites to prevent lipohypertrophy that impairs insulin absorption. 1
• Monitor glucose at every clinical visit to evaluate adequacy and detect over-basalization. 1

Avoiding Over-Basalization

• If basal insulin exceeds 0.5–1.0 units/kg/day without achieving fasting glucose goals, reassess the regimen rather than escalating further. 1

Common Pitfall

NPH insulin has greater metabolic effect during the night compared to glargine, which shifts its peak action to morning hours. 2 This pharmacokinetic difference explains why NPH may cause more nocturnal hypoglycemia despite being the guideline-recommended first choice—making long-acting analogs preferable when nocturnal hypoglycemia becomes problematic. 1